[HTML][HTML] Correlates of immunity to Group A Streptococcus: a pathway to vaccine development
H Frost, JL Excler, S Sriskandan, A Fulurija - npj Vaccines, 2023 - nature.com
Understanding immunity in humans to Group A Streptococcus (Strep A) is critical for the
development of successful vaccines to prevent the morbidity and mortality attributed to Strep …
development of successful vaccines to prevent the morbidity and mortality attributed to Strep …
Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease—streptococcal vaccine development: a national heart, lung and …
A Fulurija, MW Cunningham, N Korotkova… - BMJ Global …, 2023 - gh.bmj.com
Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that
causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and …
causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and …
The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
J Vekemans, F Gouvea-Reis, JH Kim… - Clinical Infectious …, 2019 - academic.oup.com
Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated
burden of acute and chronic disease globally. A 2018 World Health Assembly resolution …
burden of acute and chronic disease globally. A 2018 World Health Assembly resolution …
[HTML][HTML] Status of research and development of vaccines for Streptococcus pyogenes
Streptococcus pyogenes is an important global pathogen, causing considerable morbidity
and mortality, especially in low and middle income countries where rheumatic heart disease …
and mortality, especially in low and middle income countries where rheumatic heart disease …
[HTML][HTML] Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial
Streptococcus pyogenes causes at least 750 million infections and more than 500,000
deaths each year. No vaccine is currently available for S. pyogenes and the use of human …
deaths each year. No vaccine is currently available for S. pyogenes and the use of human …
[HTML][HTML] A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study
J Osowicki, KI Azzopardi, L Fabri, HR Frost… - The Lancet …, 2021 - thelancet.com
Background Streptococcus pyogenes is a leading cause of infection-related morbidity and
mortality. A reinvigorated vaccine development effort calls for new clinically relevant human …
mortality. A reinvigorated vaccine development effort calls for new clinically relevant human …
Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies
T Rivera-Hernandez, MS Rhyme, AJ Cork, S Jones… - MBio, 2020 - Am Soc Microbiol
Recent global advocacy efforts have highlighted the importance of development of a vaccine
against group A Streptococcus (GAS). Combo5 is a non-M protein-based vaccine that …
against group A Streptococcus (GAS). Combo5 is a non-M protein-based vaccine that …
Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): establishing a group A Streptococcus pharyngitis human infection study
J Osowicki, KI Azzopardi, C Baker, CS Waddington… - Vaccine, 2019 - Elsevier
Abstract Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen
responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine …
responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine …
Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models
ABSTRACT Group A Streptococcus (GAS) is an important human pathogen responsible for
both superficial infections and invasive diseases. Autoimmune sequelae may occur upon …
both superficial infections and invasive diseases. Autoimmune sequelae may occur upon …
Molecular epidemiology, ecology, and evolution of group A streptococci
DE Bessen, PR Smeesters, BW Beall - Microbiology spectrum, 2018 - Am Soc Microbiol
The clinico-epidemiological features of diseases caused by group A streptococci (GAS) is
presented through the lens of the ecology, population genetics, and evolution of the …
presented through the lens of the ecology, population genetics, and evolution of the …